Postmenopausal Osteoporosis

Postmenopausal osteoporosis, also called osteoporosis type I, usually develops in women after menopause. It is characterised by a sharp drop in estrogen levels. These changes lead to bone loss (decrease in bone mineral density), mostly in the trabecular (spongy) bone within the hard bone cortex. This increases the risk of bone fractures and can lead to disability or even death.

Showing all 8 results

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
11/2018
462,00 
view product
Max: 5
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
07/2019
462,00 
view product
Max: 10
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
10/2019
462,00 
view product
Max: 6
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
04/2020
462,00 
view product
Max: 8
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
09/2020
462,00 
view product
Max: 3
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
-80°C
01/2021
547,00 
view product
Max: 3
Min: 1
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
2-8°C / -80°C
06/2022
598,00 
view product
Max: 20
Min: 3
Step: 1
RANKL
Monoclonal Antibody
Prolia®
60 mg/mL
3 mg
2-8°C / -80°C
10/2022
598,00 
view product
Max: 15
Min: 3
Step: 1

Not looking for Postmenopausal Osteoporosis?

Search our therapeutic molecules product database

Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.

we are recruiting